Payment overview · 2025
General Payments
$1,184.33
15 reported records · 7 companies
Healthcare provider profile · identity verified
Lynn M Wung, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBIA, MO · NPI 1730133174
Verified facts
What the public records show
CMS Open Payments records show Lynn M Wung, M.D. received $1,184.33 in general payments during 2025 across 15 reported records.
GlaxoSmithKline, LLC. accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $371.47 | 31.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $252.66 | 21.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $193.09 | 16.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $178.99 | 15.1% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $96.93 | 8.2% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $72.45 | 6.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.74 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,184.33 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $252.66 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $123.39 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.09 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $123.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $107.53 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $96.93 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $72.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $70.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.84 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 19 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 349 | 73 |
| Losartan Potassium | Losartan Potassium | 224 | 57 |
| Omeprazole | Omeprazole | 217 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 209 | 59 |
| Lisinopril | Lisinopril | 180 | 39 |
| Metformin Hcl | Metformin Hcl | 154 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 31 |
| Pregabalin | Pregabalin | 147 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 28 |
| Montelukast Sodium | Montelukast Sodium | 116 | 23 |
| Gabapentin | Gabapentin | 115 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 15 |
| Simvastatin | Simvastatin | 104 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 20 |
| Metformin Hcl Er | Metformin Hcl | 87 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 13 |
| Trazodone Hcl | Trazodone Hcl | 72 | 18 |
| Tramadol Hcl | Tramadol Hcl | 69 | 17 |
| Sertraline Hcl | Sertraline Hcl | 66 | 18 |
| Mounjaro | Tirzepatide | 64 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 13 |
| Clonazepam | Clonazepam | 62 | 13 |
| Potassium Chloride | Potassium Chloride | 62 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Prednisone | Prednisone | 56 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Furosemide | Furosemide | 54 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | suppressed |
| Spironolactone | Spironolactone | 52 | 12 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Eliquis | Apixaban | 48 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Ozempic | Semaglutide | 46 | 11 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Famotidine | Famotidine | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,184.33 · 15 records | GlaxoSmithKline, LLC. | AIRSUPRA, APRETUDE, AREXVY, IBSRELA, JARDIANCE, MOUNJARO, Ozempic, PENMENVY, SHINGRIX, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error